Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PAREXEL Acquires Liquent | Contract Pharma

What are you searching for?

Sign in
Breaking News

PAREXEL Acquires Liquent

Expands regulatory capabilities with InSight platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PAREXEL International has acquired all outstanding equity securities of Liquent, Inc., a global provider of Regulatory Information Management (RIM) solutions, for approximately $72 million. Liquent provides an integrated platform of software solutions for regulatory submissions and product registration management, as well as a range of business process outsourcing capabilities. Headquartered in Horsham, PA, with additional offices in the UK, Germany and India, Liquent has nearly 300 employees.  
 
Josef von Rickenbach, chairman and chief executive officer of PAREXEL, said, “The acquisition of Liquent further strengthens our regulatory capabilities by adding a robust information technology platform. Through Liquent’s flagship software platform, InSight, our clients will have access to comprehensive regulatory agency submission planning, viewing, tracking, publishing, and registration management throughout the entire lifecycle of a medicinal entity. We are pleased to be able to provide this new offering and believe that it will enhance the portfolio of products and services that we provide through our Perceptive Informatics business.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics